Baxter International BAX NYSE · Healthcare · United States
$25.39 +0.00% +$0.00
Summary
33 / 100 · Bulios Score
What speaks for it
- The price moves less than the market (beta 0.67).
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- It cut its dividend by 50% last year.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 0.7% a year over 5 years. Over the last 3 years it grew by 3.8% a year. For the next fiscal year analysts expect revenue to grow by 4.3%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $723.0M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 8.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.16%
You receive $0.04 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 14
- Hold 20
- Sell 2
Today's price within the analysts' price targets
The average target of $23.6 is 7.1% below today's price. 39% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Medical Products And Therapies 49%
- Healthcare Systems and Technologies 28%
- Pharmaceuticals 23%
By region
- UNITED STATES 54%
- Western Europe, Canada, Japan, Australia and New Zealand 33%
- EMEA 12%
Medical Products And Therapies brings in 49% of revenue.
Segments in detail